Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

SpeeDx gets $15M in Series B funding

Executive Summary

Molecular diagnostic firm SpeeDx Pty. Ltd. raised $15M through a Series B financing from Northpond Ventures. The company’s flagship product ResistancePlus MG} will soon be commencing US clinical trials for detecting Mycoplasma genitalium and genetic markers linked to antibiotic resistance of the common macrolide frontline treatment. Preclinical testing is wrapping up in preparation for US trials for ResistancePlus GC for determining the susceptibility of gonorrhoea infections to ciprofloxacin treatment. (It has breakthrough device designation by the FDA.)
Deal Industry
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies